Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · PAVmed Inc. (PAVM)

PAVmed: Subsidiary Lucid Diagnostics Sells $15.0 Million of Series C Preferred Stock

Neutral Impact 3 of 5 financing Written later

PAVmed's subsidiary Lucid Diagnostics sold 15,000 shares of newly designated Series C Convertible Preferred Stock at $1,000 per share, raising gross proceeds of $15.0 million, with closing on the same day. The filing also discloses a registration rights agreement under which Lucid Diagnostics agreed to register resale of the common stock issuable on conversion, which could add shares to the market.

Key points

  • Subscription agreements dated effective October 21, 2026, with certain accredited investors
  • 15,000 Series C Convertible Preferred shares sold at $1,000 per share; gross proceeds $15.0 million
  • Certificate of Designations filed in Delaware on the closing date; Lucid Diagnostics agreed to file a resale registration statement for underlying common stock

The filing

CompanyPAVmed Inc. (PAVM)
Form8-K, current report
Filed with the SECOct 22, 2026, 5:28 PM ET
Accession number0001493152-26-048138

Items reported: 1.01 Material Definitive Agreement3.03 Change to Shareholder Rights

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.